Identification of Bioactive Compound from Microalga BTM 11 as Hepatitis C Virus RNA Helicase Inhibitor
ABSTRACT: Hepatitis C virus
(HCV) is the major causative agent of chronic liver disease. Recently, the
inhibition of NS3 RNA helicase/ATPase activity is being explored as the
specifically targeted antiviral therapy (STAT) against HCV infection. This study
was aimed to elucidate potential candidates for anti-HCV therapy derived from
Indonesian indigenous microalgae. The microalga designated as BTM 11 was
isolated and cultured. Methanol extract of BTM 11 was screened as the opponent of
purified HCV NS3 RNA helicase enzyme through colorimetric ATPase assay.
Screening of chemical compound and fractionation by using gel filtration
chromatography with eluent of methanol : chloroform (1:99) were conducted for identification
and isolation of the bioactive compounds. The third fraction of fractionated
sample showed a relatively strong ATPase inhibitory effect (81.23 ± 2.25 %)
compared to the negative control. Further analysis of third fraction using thin
layer chromatography (TLC) with eluent of chloroform : methanol (9:2) gave two
spots with the Rf value of 0.8 and 0.37, respectively. In addition, high
performance liquid chromatography (HPLC) analysis showed absorption peak with
the highest abundance at the retention time of 12.483 and 16.617 minutes which
absorbed at 266 and 230 nm wavelenght, respectively. According to those
analyses, this study suggests that bioactive compounds derived from BTM 11 were
classified as the groups of flavonoids and feasible as potential candidates for
anti-HCV therapy through the inhibitory effect of NS3 RNA helicase/ATPase
activity.
Penulis: Apon Zaenal Mustopa,
Rifqiyah Nur Umami, Prabawati Hyunita Putri, Dwi Susilaningsih, & Hilda
Farida
Kode Jurnal: jpbiologidd150840
